| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8396828 | Toxicon | 2013 | 5 Pages |
Abstract
The scorpion antivenom marketed in the United States is extremely effective, but too costly to justify its use in most clinical situations. Formulary committees should restrict the use of this antivenom to only the most severe scorpion envenomations.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry, Genetics and Molecular Biology (General)
Authors
Edward P. Armstrong, Maja Bakall, Grant H. Skrepnek, Leslie V. Boyer,